Evelo Biosciences Issued With U.S. Patent For Pharmaceutical Compositions of Veillonella Parvula Bacteria

Evelo Biosciences' new patent claims encompass Veillonella parvula oral formulations and are an addition to the company's increasing intellectual property (I.P.) portfolio for SINTAX therapies.

FREMONT, CA: Evelo Biosciences announces that the U.S. Patent and Trademark Office has issued a new composition of matter patent (No. 11,090,341) for medications, including pharmaceutical formulations of Veillonella parvula bacteria.

"The grant of this patent is further confirmation that pharmaceutical compositions containing single strains of naturally occurring bacteria selected for their potential therapeutic properties are patent-eligible," said Dr. Mark Bodmer, Chief Scientific Officer and President of R&D of Evelo. "These compositions do not occur in nature and so are patentable in a similar way to more conventional novel medicines. We are pleased that this has again been recognized by the U.S. Patent and Trademark Office, providing vital I.P. covering for Evelos leading innovation in developing effective, safe, oral SINTAX medicines."

This patent is an important addition to the Company's significant and increasing intellectual property (I.P.) portfolio for SINTAX therapies that target the small intestinal axis. This new patent's issued claims encompass Veillonella parvula oral formulations, including EDP1867, which is now being tested in a Phase 1b clinical trial for the treatment of atopic dermatitis.

"The patent specification also discloses the use of extracellular vesicles (E.V.s) derived from Veillonella as orally-delivered medicines," continued Dr. Bodmer. "Preclinical data suggest that E.V.s may be effective as oral gut-restricted medicines with systemic effects. Their physical properties may enable increased engagement of the small intestinal axis and, so, increased efficacy. Our first E.V. product candidate, EDP2939, is on-track to enter the clinic in 2022 as part of the continuing expansion of Evelos product portfolio and its underlying I.P."

Evelo Biosciences is a clinical-stage biotechnology company developing orally delivered medicines that act on SINTAX, the small intestinal axis, to have systemic therapeutic effects. SINTAX plays a central role in governing the immune, metabolic, and neurological systems.

Evelo currently has four product candidates in development: EDP1815, EDP1867, and EDP2939 to treat inflammatory diseases and EDP1908 for the treatment of cancer. Evelo is advancing additional product candidates in other disease areas.